Capital B reported a net loss of €69.5 million in the first half of 2026, primarily due to a noncash €67.5 million impairment charge on its Bitcoin holdings, reflecting prices as of June 30. Despite the loss, the company increased its Bitcoin reserves by 11.2% to 3,139 BTC by June and further to 3,538 BTC by September, supported by €27.5 million in fundraising during H1 and additional capital raises afterward. Revenue grew 3.5% to €5.85 million, and the company maintained its strategic focus on expanding its Bitcoin treasury while its technology businesses showed positive operating EBITDA. Capital B's financials indicate ongoing investment in cryptocurrency despite accounting losses, with liquidity sufficient for the next 12 months based on internal forecasts.
Capital B's reported €69.5 million net loss in H1 2026 provides context for cryptocurrency market activity. For readers following crypto markets, here is Pluang's snapshot as of Oct 16, 2026 15:21 WIB: out of 50 major cryptocurrencies priced on Pluang, 45 rose and 3 fell today. Notable gainers include FIL at Rp20.501 (+10.35%), ALGO at Rp2.144 (+9.33%), and EOS at Rp12.649 (+8.13%).
Vereigen Media's Verified Content Engagement (VCE) solution won Gold at the 2026 TITAN Business Awards for improving B2B lead quality through first-party data, human verification, and engagement validation. This approach helps marketing teams deliver...
UBS Group AG has officially notified that it holds 7,768,727 shares in Bang & Olufsen A/S, representing 5.27% of the company's total share capital and voting rights as of October 9, 2026. This disclosure is made in compliance with the Danish Capital ...
Norsk Hydro will publish its third-quarter 2026 financial results on October 23, 2026, at 07:00 CEST. The company's CEO and CFO will present the results via a live webcast at 08:30 CEST the same day, allowing investors to ask questions online. There ...
On October 14, 2026, Michael Brierley, a Non-Executive Director of Admiral Group plc, and his wife Rachel Brierley acquired shares of the company through a dividend reinvestment trading plan. The transactions involved purchasing ordinary shares at pr...
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
